A phase 1b/2 trial of the PLK1 inhibitor onvansertib in combination with FOLFIRI-bev in 2L treatment of KRAS-mutated (mKRAS) metastatic colorectal carcinoma (mCRC)

被引：5

作者：

Lenz, Heinz-Josef

Kasi, Anup

Mendelsohn, Lawrence

Cannon, Timothy Lewis

Starr, Jason S.

Hubbard, Joleen M.

Bekaii-Saab, Tanios S.

Ridinger, Maya

Samuelsz, Errin

Ruffner, Katherine L.

Erlander, Mark G.

Ahn, Daniel H.

机构：

[1] Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90007 USA

[2] Univ Kansas, Ctr Canc, Westwood, KS USA

[3] Little Rock Hem Onc Assoc, Little Rock, AR USA

[4] Inova Schar Canc Inst, Fairfax, VA USA

[5] Univ Florida, Hlth Canc Ctr, Jacksonville, FL USA

[6] Mayo Clin, Rochester, MN USA

[7] Mayo Clin, Div Hematol Oncol, Phoenix, AZ USA

[8] Cardiff Oncol, San Diego, CA USA

[9] Mayo Clin, Phoenix, AZ USA

来源：

关键词：

D O I：

10.1200/JCO.2022.40.4_suppl.100

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

100

引用

页数：3